Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million , up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code Real-world data published on
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery – – A retrospective clinical study of the Pressure-Enabled Drug
DENVER --(BUSINESS WIRE)--Mar. 21, 2024-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from
– Q4 sales of approximately $5.7 million represent 77% growth versus 2022 – – Q4 and full year gross margin of approximately 90% and 86% respectively – – Full year 2024 sales growth expected to exceed 50% – – Conference call scheduled for Monday, April 1, 2024 , at 9:00 a.m.
– Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate designed to overcome biologic barriers in liver and pancreatic tumors – Nelitolimod is currently being evaluated in three Phase 1/1b studies in adults with liver and pancreatic cancers in
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, treatment refractory, and higher disease burden patients, further validating previous data in the